XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2022
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:
 
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2022202120222021
Included in research and development expense$126 $72 $460 $112 
Included in selling, general and administrative expense929 964 1,747 1,192 
Total stock-based compensation expense$1,055 $1,036 $2,207 $1,304 
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards
The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
 
Six Months Ended June 30,
20222021
Risk-free interest rate1.87 %0.94 %
Dividend yield%%
Expected volatility of Cardiff Oncology common stock106 %108 %
Expected term6.0 years6.0 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding
A summary of stock option activity and changes in stock options outstanding is presented below:
 
Total OptionsWeighted-Average
Exercise Price
Per Share
Intrinsic
Value
Balance outstanding, December 31, 20213,771,984 $7.13 $6,405,258 
Granted1,731,136 $3.15  
Canceled / Forfeited(371,125)$4.77  
Expired(800)$165.84  
Balance outstanding, June 30, 20225,131,195 $5.93 $80,809 
Exercisable at June 30, 20222,030,219 $7.49 $34,443 
Vested and expected to vest at June 30, 20225,042,299 $5.95 $77,880 
Summary of Warrant Activity and Changes in Warrants Outstanding
A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
 
Total WarrantsWeighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual
Term
Balance outstanding, December 31, 20214,490,159 $5.80 3.0 years
Balance outstanding, June 30, 20224,490,159 $5.80 2.5 years
Schedule of Preferred Stock
A summary of our Company's classes of preferred stock is presented below:
Shares outstanding
ClassPar valueShares designatedLiquidation preferenceAs of June 30,
2022
As of December 31,
2021
Series A Convertible Preferred Stock$0.001 277,100 $606,000 60,600 60,600 
Series B Convertible Preferred Stock$0.001 8,860 None— — 
Series C Convertible Preferred Stock$0.001 200,000 None— — 
Series D Convertible Preferred Stock$0.0001 154,670 None— — 
Series E Convertible Preferred Stock$0.001 865,824 None327,509 655,044